Healthcare

SB 1334 amends Pennsylvania's Medical Practice Act to formally establish licensing requirements and definitions for various medical imaging and allied health professionals. The bill directly affects respiratory therapists, perfusionists, genetic counselors, prosthetists, orthotists, pedorthists, and new categories including medical imaging professionals, radiation therapists, and radiologist assistants. Key provisions introduce specific definitions for imaging modalities like computed tomography and magnetic resonance imaging while repealing outdated rules regarding radiologic procedures. Additionally, the legislation sets forth general qualification standards and outlines the framework for issuing licenses and certificates to these newly recognized roles.

SB 507 amends Pennsylvania's medical licensing law to reestablish the State Board of Medical Education and Licensure as the State Board of Medicine and update its structure. It directly affects midwifery professionals by creating three new license categories: midwifery, nurse-midwife, and certified midwife. The bill establishes specific requirements and definitions for these licenses under the board's authority. This change clarifies licensing pathways for midwifery practitioners within the state's medical regulatory framework. The bill passed final passage on October 21, 2025.

SB 95 amends Pennsylvania's Pharmacy Act to create a 180-day provisional license for pharmacists moving from other states, allowing them to practice without demonstrating competency under Pennsylvania's requirements. It also permits emergency medical services providers to distribute naloxone dose packages for opioid overdose reversal under specific conditions, including a Department of Health standing order and voluntary distribution without liability. Additionally, the bill requires pharmacies to disclose prescription drug prices (brand vs. generic), cost-sharing amounts, and health insurance options upon customer request. These changes aim to improve pharmacist mobility, expand naloxone access, and increase price transparency for consumers.